Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Decrease in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 7,400 shares, a decrease of 53.2% from the June 15th total of 15,800 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 24,500 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC raised its position in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the period. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities and Exchange Commission. 5.06% of the stock is owned by institutional investors.

Akari Therapeutics Trading Down 0.9 %

NASDAQ AKTX opened at $3.50 on Friday. The firm has a 50-day simple moving average of $2.41 and a 200 day simple moving average of $2.24. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Akari Therapeutics in a report on Saturday. They set a “sell” rating for the company.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.